{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T17:13:46Z","timestamp":1789492426256,"version":"build-2803163510"},"reference-count":98,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["RF-2024-12380079"],"award-info":[{"award-number":["RF-2024-12380079"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jhep.2026.07.020","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T16:23:38Z","timestamp":1789489418000},"page":"727-739","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Liver transplantation for primary liver cancers in the era of transplant oncology"],"prefix":"10.1016","volume":"85","author":[{"given":"Vincenzo","family":"Mazzaferro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7260-532X","authenticated-orcid":false,"given":"Matthias","family":"Pinter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjana","family":"Pillai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Sposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parissa","family":"Tabrizian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2026.07.020_bib1","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S0140-6736(09)61086-2","article-title":"Challenges in evaluating surgical innovation","volume":"374","author":"Ergina","year":"2009","journal-title":"The Lancet"},{"key":"10.1016\/j.jhep.2026.07.020_bib2","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/S0140-6736(09)61116-8","article-title":"No surgical innovation without evaluation: the IDEAL recommendations","volume":"374","author":"McCulloch","year":"2009","journal-title":"The Lancet"},{"key":"10.1016\/j.jhep.2026.07.020_bib3","first-page":"1","article-title":"Phase III precision medicine clinical trial designs that integrate treatment and biomarker evaluation","volume":"3","author":"Polley","year":"2019","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.jhep.2026.07.020_bib4","doi-asserted-by":"crossref","first-page":"4552","DOI":"10.1158\/1078-0432.CCR-15-0124","article-title":"Failures in phase III: causes and consequences","volume":"21","author":"Seruga","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jhep.2026.07.020_bib5","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/BF01659064","article-title":"Surgical treatment of hepatocellular carcinoma: experience with liver resection and transplantation in 198 patients","volume":"15","author":"Ringe","year":"1991","journal-title":"World J Surg"},{"key":"10.1016\/j.jhep.2026.07.020_bib6","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1002\/1097-0142(19911115)68:10<2095::AID-CNCR2820681002>3.0.CO;2-Y","article-title":"Accelerated growth rates of recurrent hepatocellular carcinoma after liver transplantation","volume":"68","author":"Yokoyama","year":"1991","journal-title":"Cancer"},{"key":"10.1016\/j.jhep.2026.07.020_bib7","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/00000658-199109000-00005","article-title":"Hepatic resection versus transplantation for hepatocellular carcinoma","volume":"214","author":"Iwatsuki","year":"1991","journal-title":"Ann Surg"},{"key":"10.1016\/j.jhep.2026.07.020_bib8","article-title":"Transplant oncology \u2013 current indications and strategies to advance the field","volume":"6","author":"Krendl","year":"2024","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2026.07.020_bib9","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1111\/j.1432-2277.2011.01274.x","article-title":"Evidence-based development of liver allocation: a review","volume":"24","author":"Merion","year":"2011","journal-title":"Transpl Int"},{"key":"10.1016\/j.jhep.2026.07.020_bib10","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jhep.2013.10.010","article-title":"A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list","volume":"60","author":"Vitale","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.07.020_bib11","doi-asserted-by":"crossref","DOI":"10.1111\/ajt.13408","article-title":"A multistep, consensus-based approach to organ allocation in liver transplantation: toward a \u201cblended principle model.\u201d","author":"Cillo","year":"2015","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jhep.2026.07.020_bib12","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJM199603143341104","article-title":"Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis","volume":"334","author":"Mazzaferro","year":"1996","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jhep.2026.07.020_bib13","doi-asserted-by":"crossref","DOI":"10.1002\/lt.22365","article-title":"Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience","volume":"17","author":"Mazzaferro","year":"2011","journal-title":"Liver Transplant"},{"key":"10.1016\/j.jhep.2026.07.020_bib14","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jhep.2020.03.018","article-title":"Including mRECIST in the Metroticket 2.0 criteria improves prediction of hepatocellular carcinoma-related death after liver transplant","volume":"73","author":"Cucchetti","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.07.020_bib15","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2012.05.052","article-title":"Liver transplantation for hepatocellular carcinoma: a model including \u03b1-fetoprotein improves the performance of milan criteria","volume":"143","author":"Duvoux","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2026.07.020_bib16","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1097\/LVT.0000000000000551","article-title":"Enhancing the prognostic accuracy of the RETREAT score with AFP-L3 and DCP tumor markers","volume":"31","author":"Norman","year":"2025","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2026.07.020_bib17","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/B978-0-443-21901-6.00001-X","article-title":"Transplant oncology: concept, history, and evolution","author":"Mazzaferro","year":"2025","journal-title":"Transpl Oncol"},{"key":"10.1016\/j.jhep.2026.07.020_bib18","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0889-8553(21)00342-3","article-title":"Surgical technique of orthotopic liver transplantation","volume":"17","author":"Makowka","year":"1988","journal-title":"Gastroenterol Clin North Am"},{"key":"10.1016\/j.jhep.2026.07.020_bib19","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1016\/S0140-6736(99)90002-8","article-title":"Guidelines for selection of patients for liver transplantation in the era of donor-organ shortage","volume":"354","author":"Neuberger","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2026.07.020_bib20","doi-asserted-by":"crossref","DOI":"10.1111\/j.1600-6143.2004.00703.x","article-title":"The survival benefit of liver transplantation","author":"Merion","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jhep.2026.07.020_bib21","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2024.08.028","article-title":"EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma","volume":"82","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.07.020_bib22","first-page":"815","article-title":"The 2024 ILTS-ILCA consensus recommendations for liver transplantation for HCC and intrahepatic cholangiocarcinoma","volume":"31","author":"Kodali","year":"2025","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2026.07.020_bib23","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.cgh.2021.07.048","article-title":"National trends and waitlist outcomes of locoregional therapy among liver transplant candidates with hepatocellular carcinoma in the United States","volume":"20","author":"Kwong","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2026.07.020_bib24","article-title":"International study on the outcome of locoregional therapy for liver transplant in hepatocellular carcinoma beyond Milan criteria","volume":"3","author":"Degroote","year":"2021","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2026.07.020_bib25","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1053\/j.gastro.2021.07.033","article-title":"Downstaging outcomes for hepatocellular carcinoma: results from the multicenter evaluation of reduction in tumor size before liver transplantation (MERITS-LT) consortium","volume":"161","author":"Mehta","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2026.07.020_bib26","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S1470-2045(20)30224-2","article-title":"Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b\/3 trial","volume":"21","author":"Mazzaferro","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2026.07.020_bib27","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1097\/HEP.0000000000001231","article-title":"Downstaging of hepatocellular carcinoma before liver transplantation: results from a national multicenter prospective cohort study","volume":"82","author":"Xu","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2026.07.020_bib28","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1002\/lt.24169","article-title":"Downstaging hepatocellular carcinoma: a systematic review and pooled analysis","volume":"21","author":"Parikh","year":"2015","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2026.07.020_bib29","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.cgh.2022.02.018","article-title":"UNOS down-staging criteria for liver transplantation of hepatocellular carcinoma: systematic review and meta-analysis of 25 studies","volume":"21","author":"Tan","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2026.07.020_bib30","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1002\/hep.27752","article-title":"Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria","volume":"61","author":"Yao","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2026.07.020_bib31","first-page":"779","article-title":"Ten-year outcomes of liver transplant and downstaging for hepatocellular carcinoma","volume":"157","author":"Tabrizian","year":"2022","journal-title":"JAMA Surg"},{"key":"10.1016\/j.jhep.2026.07.020_bib32","doi-asserted-by":"crossref","first-page":"e312","DOI":"10.1016\/S1470-2045(23)00186-9","article-title":"Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept","volume":"24","author":"Vitale","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2026.07.020_bib33","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1111\/cas.16194","article-title":"Conversion therapy for advanced hepatocellular carcinoma in the era of precision medicine: current status, challenges and opportunities","volume":"115","author":"Wang","year":"2024","journal-title":"Cancer Sci"},{"key":"10.1016\/j.jhep.2026.07.020_bib34","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1002\/hep.30413","article-title":"Alpha-fetoprotein decrease from > 1,000 to < 500 ng\/mL in patients with hepatocellular carcinoma leads to improved posttransplant outcomes","volume":"69","author":"Mehta","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2026.07.020_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2026.02.019","article-title":"Efficacy of liver transplantation after response to atezolizumab-bevacizumab downstaging of intermediate and advanced hepatocellular carcinoma (ImmunoXXL)","volume":"85","author":"Bhoori","year":"2026","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.07.020_bib36","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jhep.2024.05.037","article-title":"Immunotherapy for hepatocellular carcinoma: the next evolution in expanding access to liver transplantation","volume":"81","author":"Li","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.07.020_bib37","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.jhep.2024.09.003","article-title":"Intention-to-treat outcomes of patients with hepatocellular carcinoma receiving immunotherapy before liver transplant: the multicenter VITALITY study","volume":"82","author":"Tabrizian","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.07.020_bib38","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0140-6736(24)02551-0","article-title":"Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study","volume":"405","author":"Sangro","year":"2025","journal-title":"The Lancet"},{"key":"10.1016\/j.jhep.2026.07.020_bib39","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(24)02575-3","article-title":"Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study","volume":"405","author":"Kudo","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2026.07.020_bib40","doi-asserted-by":"crossref","first-page":"4001","DOI":"10.1200\/JCO.2026.44.16_suppl.4001","article-title":"Camrelizumab (C) plus rivoceranib (R) with transarterial chemoembolization (TACE) vs TACE alone in unresectable hepatocellular carcinoma (uHCC): a randomized, phase 3 trial","volume":"44","author":"Jia","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2026.07.020_bib41","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2026.44.17_suppl.LBA4000","article-title":"Efficacy and safety results from EMERALD-3: a phase 3, randomized study of tremelimumab plus durvalumab with or without lenvatinib combined with transarterial chemoembolization (TACE) in participants (pts) with unresectable embolization-eligible hepatoce\u2026","volume":"44","author":"Abou-Alfa","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2026.07.020_bib42","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1016\/j.annonc.2025.05.542","article-title":"LBA2 TALENTACE: a phase III, open-label, randomized study of on-demand transarterial chemoembolization (TACE) combined with atezolizumab + bevacizumab (Atezo+Bev) or on-demand TACE alone in patients with systemically untreated, intermediate-to-high burde\u2026","volume":"36","author":"Dong","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2026.07.020_bib43","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2026.07.020_bib44","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/S0140-6736(25)00403-9","article-title":"Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial","volume":"405","author":"Yau","year":"2025","journal-title":"The Lancet"},{"key":"10.1016\/j.jhep.2026.07.020_bib45","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.jhep.2026.07.020_bib46","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.jhep.2026.07.020_bib47","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.jhep.2025.05.003","article-title":"Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study","volume":"83","author":"Oh","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.07.020_bib48","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jhep.2024.06.042","article-title":"Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC: a systematic review and individual patient data meta-analysis","volume":"82","author":"Rezaee-Zavareh","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.07.020_bib49","doi-asserted-by":"crossref","DOI":"10.1097\/LVT.0000000000000829","article-title":"Beyond rejection risk: identifying ideal candidates for pretransplant immune checkpoint inhibitors for HCC","author":"Aceituno","year":"2026","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2026.07.020_bib50","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/j.ajt.2024.04.007","article-title":"Pretransplant use of immune checkpoint inhibitors for hepatocellular carcinoma: a multicenter, retrospective cohort study","volume":"24","author":"Guo","year":"2024","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jhep.2026.07.020_bib51","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1097\/HEP.0000000000001163","article-title":"Outcome and management of patients with hepatocellular carcinoma who achieved a complete response to immunotherapy-based systemic therapy","volume":"81","author":"Scheiner","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2026.07.020_bib52","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.jhep.2025.03.033","article-title":"Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC","volume":"83","author":"Rimassa","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.07.020_bib53","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"The Lancet"},{"key":"10.1016\/j.jhep.2026.07.020_bib54","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.jhep.2026.07.020_bib55","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1159\/000541646","article-title":"Probability of lymph node metastases in patients undergoing adequate lymphadenectomy during surgery for intrahepatic cholangiocarcinoma: a retrospective multicenter study","volume":"14","author":"Sposito","year":"2024","journal-title":"Liver Cancer"},{"key":"10.1016\/j.jhep.2026.07.020_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(22)01888-8","article-title":"Survival benefit of adequate lymphadenectomy in patients undergoing liver resection for clinically node negative intrahepatic cholangiocarcinoma","author":"Sposito","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.07.020_bib57","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1097\/HEP.0000000000000046","article-title":"Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: the STAMP randomized trial","volume":"77","author":"Jeong","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2026.07.020_bib58","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/jso.20772","article-title":"Incidence and prognostic values of lymph node metastasis in operable hepatocellular carcinoma and evaluation of routine complete lymphadenectomy","volume":"96","author":"Sun","year":"2007","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.jhep.2026.07.020_bib59","doi-asserted-by":"crossref","DOI":"10.1002\/hep.28744","article-title":"Liver transplantation for \u201cvery early\u201d intrahepatic cholangiocarcinoma: international retrospective study supporting a prospective assessment","volume":"64","author":"Sapisochin","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2026.07.020_bib60","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1002\/lt.25737","article-title":"Analysis of liver resection versus liver transplantation on outcome of small intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma in the setting of cirrhosis","volume":"26","author":"De Martin","year":"2020","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2026.07.020_bib61","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/ajt.16906","article-title":"Survival following liver transplantation for locally advanced, unresectable intrahepatic cholangiocarcinoma","volume":"22","author":"McMillan","year":"2022","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jhep.2026.07.020_bib62","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S2468-1253(18)30045-1","article-title":"Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series","volume":"3","author":"Lunsford","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2026.07.020_bib63","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1007\/s13304-021-01078-4","article-title":"Hepatocellular cancer selection systems and liver transplantation: from the tower of babel to an ideal comprehensive score","volume":"73","author":"Lerut","year":"2021","journal-title":"Updates Surg"},{"key":"10.1016\/j.jhep.2026.07.020_bib64","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1053\/j.gastro.2017.09.025","article-title":"Metroticket 2.0 model for analysis of competing risks of death after liver transplantation for hepatocellular carcinoma","volume":"154","author":"Mazzaferro","year":"2018","journal-title":"Gastroenterology"},{"issue":"15.","key":"10.1016\/j.jhep.2026.07.020_bib65","article-title":"The prognostic impact of preoperative CA19-9 on resectable cholangiocarcinoma: a comprehensive systematic review and meta-analysis","author":"Wang","year":"2024","journal-title":"Discover Oncol"},{"key":"10.1016\/j.jhep.2026.07.020_bib66","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1002\/cncr.34854","article-title":"The association of carbohydrate antigen 19-9 response with radiologic response and survival in intrahepatic cholangiocarcinoma: a prospective cohort study","volume":"129","author":"Cai","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.jhep.2026.07.020_bib67","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1002\/lt.23904","article-title":"Alpha-fetoprotein level > 1000 ng\/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria","volume":"20","author":"Hameed","year":"2014","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2026.07.020_bib68","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1600-6143.2009.02750.x","article-title":"Progression of alphafetoprotein before liver transplantation for hepatocellular carcinoma in cirrhotic patients: a critical factor","volume":"10","author":"Vibert","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jhep.2026.07.020_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2025.110193","article-title":"Vascular resection and reconstruction in surgery for advanced intrahepatic cholangiocarcinoma \u2013 single center experience with 59 vascular resections","volume":"51","author":"Lang","year":"2025","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.jhep.2026.07.020_bib70","doi-asserted-by":"crossref","DOI":"10.3389\/ti.2024.13641","article-title":"Liver transplantation for intrahepatic cholangiocarcinoma after chemotherapy and radioembolization: an intention-to-treat study","volume":"37","author":"Maspero","year":"2024","journal-title":"Transpl Int"},{"key":"10.1016\/j.jhep.2026.07.020_bib71","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.jhep.2023.03.032","article-title":"Are patients with hepatocellular carcinoma and portal vein tumour thrombosis candidates for liver transplantation?","volume":"78","author":"Soin","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.07.020_bib72","doi-asserted-by":"crossref","first-page":"e219","DOI":"10.1016\/j.jhep.2023.10.031","article-title":"Patients with hepatocellular carcinoma and portal vein tumour thrombosis after successful downstaging may be candidates for liver transplantation: a meta-analysis","volume":"80","author":"Liu","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.07.020_bib73","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1002\/lt.24782","article-title":"The clinical outcomes of patients with portal vein tumor thrombi after living donor liver transplantation","volume":"23","author":"Choi","year":"2017","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2026.07.020_bib74","doi-asserted-by":"crossref","DOI":"10.1097\/HEP.0000000000001801","article-title":"Outcomes of Y90-radioembolization as downstaging to liver transplantation in patients with hepatocellular carcinoma and tumoral portal vein thrombosis","author":"Sposito","year":"2026","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2026.07.020_bib75","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1002\/lt.26257","article-title":"Deceased donor liver transplantation after radioembolization for hepatocellular carcinoma and portal vein tumoral thrombosis: a pilot study","volume":"27","author":"Serenari","year":"2021","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2026.07.020_bib76","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1097\/TP.0000000000005204","article-title":"Transarterial radioembolization can downstage intermediate and advanced hepatocellular carcinoma to liver transplantation","volume":"109","author":"Berardi","year":"2025","journal-title":"Transplantation"},{"key":"10.1016\/j.jhep.2026.07.020_bib77","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s00534-009-0063-0","article-title":"Laparoscopic liver resection facilitates salvage liver transplantation for hepatocellular carcinoma","volume":"16","author":"Laurent","year":"2009","journal-title":"J Hepatobiliary Pancreat Surg"},{"key":"10.1016\/j.jhep.2026.07.020_bib78","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1097\/01.sla.0000098621.74851.65","article-title":"Resection prior to liver transplantation for hepatocellular carcinoma","volume":"238","author":"Belghiti","year":"2003","journal-title":"Ann Surg"},{"key":"10.1016\/j.jhep.2026.07.020_bib79","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1097\/SLA.0000000000004258","article-title":"Hypothermic oxygenated liver perfusion (hope) prevents tumor recurrence in liver transplantation from donation after circulatory death","volume":"272","author":"Mueller","year":"2020","journal-title":"Ann Surg"},{"key":"10.1016\/j.jhep.2026.07.020_bib80","article-title":"HCC recurrence in liver transplants treated with hypothermic oxygenated machine perfusion: an international matched cohort study","volume":"8","author":"Eden","year":"2026","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2026.07.020_bib81","article-title":"The role of ischaemia-reperfusion injury and liver regeneration in hepatic tumour recurrence","volume":"5","author":"Maspero","year":"2023","journal-title":"JHEP Rep"},{"issue":"Suppl 2","key":"10.1016\/j.jhep.2026.07.020_bib82","article-title":"Should we use living donor grafts for patients with hepatocellular carcinoma? Ethical considerations","volume":"17","author":"Pomfret","year":"2011","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2026.07.020_bib83","doi-asserted-by":"crossref","DOI":"10.1097\/TP.0000000000005427","article-title":"Live donor liver transplantation for oncologic indications","volume":"109","author":"Byrne","year":"2025","journal-title":"Transplantation"},{"key":"10.1016\/j.jhep.2026.07.020_bib84","doi-asserted-by":"crossref","DOI":"10.1001\/jamasurg.2021.3112","article-title":"Evaluation of the intention-to-treat benefit of living donation in patients with hepatocellular carcinoma awaiting a liver transplant","volume":"156","author":"Lai","year":"2021","journal-title":"JAMA Surg"},{"key":"10.1016\/j.jhep.2026.07.020_bib85","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/lt.20391","article-title":"Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression","volume":"11","author":"Vivarelli","year":"2005","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2026.07.020_bib86","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/TP.0000000000000965","article-title":"Sirolimus use in liver transplant recipients with hepatocellular carcinoma: a randomized, multicenter, open-label phase 3 trial","volume":"100","author":"Geissler","year":"2015","journal-title":"Transplantation"},{"key":"10.1016\/j.jhep.2026.07.020_bib87","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1001\/jamaoncol.2016.5116","article-title":"Validation of a risk estimation of tumor recurrence after transplant (RETREAT) score for hepatocellular carcinoma recurrence after liver transplant","volume":"3","author":"Mehta","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jhep.2026.07.020_bib88","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1097\/HEP.0000000000001289","article-title":"Determining safe washout period for immune checkpoint inhibitors prior to liver transplantation: an international retrospective cohort study","volume":"82","author":"Moeckli","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2026.07.020_bib89","first-page":"18","article-title":"Balancing tumor response and rejection risk after pre-transplant immunotherapy: a scoping review","author":"Demirors","year":"2026","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jhep.2026.07.020_bib90","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.e14624","article-title":"Immune checkpoint inhibitors as a neoadjuvant therapy pre-liver transplantation for hepatobiliary carcinoma","volume":"43","author":"Esmail","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2026.07.020_bib91","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-025-04177-6","article-title":"Humoral IgG1 responses to tumor antigens underpin clinical outcomes in immune checkpoint blockade","volume":"32","author":"Gonzalez-Kozlova","year":"2026","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2026.07.020_bib92","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/s41422-025-01171-y","article-title":"Trained immunity: induction of an inflammatory memory in disease","volume":"35","author":"Schl\u00fcter","year":"2025","journal-title":"Cell Res"},{"key":"10.1016\/j.jhep.2026.07.020_bib93","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17121930","article-title":"Updates on liquid biopsy and ctDNA in transplant oncology","volume":"17","author":"Loszko","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jhep.2026.07.020_bib94","article-title":"Feasibility of personalized and tumor-informed circulating tumor DNA assay for early recurrence detection in patients with hepatocellular carcinoma","volume":"9","author":"Abdelrahim","year":"2025","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.jhep.2026.07.020_bib95","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.21037\/jgo-24-791","article-title":"Tumor-informed circulating tumor DNA assay for surveillance post-liver transplantation in patients with hepatocellular and cholangiocarcinoma","volume":"16","author":"Abdelrahim","year":"2025","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.jhep.2026.07.020_bib96","doi-asserted-by":"crossref","first-page":"7190","DOI":"10.7150\/jca.59612","article-title":"Plasma MicroRNA panel predicts early tumor recurrence in patients with hepatocellular carcinoma after liver transplantation","volume":"12","author":"Huang","year":"2021","journal-title":"J Cancer"},{"key":"10.1016\/j.jhep.2026.07.020_bib97","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16050927","article-title":"Circulating tumor DNA profiling in liver transplant for hepatocellular carcinoma, cholangiocarcinoma, and colorectal liver metastases: a programmatic proof of concept","volume":"16","author":"Hong","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jhep.2026.07.020_bib98","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1038\/s41586-025-08668-x","article-title":"Spatial immune scoring system predicts hepatocellular carcinoma recurrence","volume":"640","author":"Jia","year":"2025","journal-title":"Nature"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827826027480?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827826027480?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T16:53:39Z","timestamp":1789491219000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827826027480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":98,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0168827826027480"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2026.07.020","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Liver transplantation for primary liver cancers in the era of transplant oncology","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2026.07.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.","name":"copyright","label":"Copyright"}]}}